Teva in talks with Trump administration on Medicaid drug pricing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
August 31, 2026 4:06 PM EDTPARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities. Â
Â
Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow, said Chris... More
